FIELD: medicine.
SUBSTANCE: invention relates to the field of medicine. Claimed is a method of determining sensitivity of kidney cancer to immunotherapy after performing nephrectomy, including diagnosis verification, performing nephrectomy of kidney cancer, sampling of tumour and normal kidney tissue to determine a level of expression of cytokines IL-4, IL-6, IL-10, TGFβ and calculation of ratio of level of cytokine expression in tumour and normal kidney tissue. If the level of cytokine expression in tumour tissue of kidney is higher than normal, therapy is considered to be indicated.
EFFECT: invention makes it possible to determine sensitivity of kidney cancer to immunotherapy on the basis of the data of cytokine expression in tumour tissue.
2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DIAGNOSING BREAST CANCER BY LEVEL OF MRNA TGEβ AND TNFα IN BLOOD PLASMA | 2019 |
|
RU2742209C1 |
| IMPROVED SUPPORTING THERAPY OF TUMOURS EXPRESSING G250 | 2005 |
|
RU2371198C2 |
| IMPROVED ADJUVANT THERAPY OF G250 EXPRESSING TUMOURS | 2005 |
|
RU2519340C2 |
| METHOD FOR PREDICTION OF CLINICAL OUTCOME IN PATIENTS WITH METASTATIC KIDNEY CANCER | 2015 |
|
RU2589286C1 |
| METHOD FOR PREDICTION OF ONCOLOGICAL SURVIVAL RATE IN PATIENTS WITH NONMETASTATIC RENAL CELL CARCINOMA AFTER MALIGNANT NEPHRECTOMY OR PARTIAL NEPHRECTOMY | 2010 |
|
RU2438127C1 |
| METHOD FOR DIAGNOSING BREAST CANCER AND OVARIAN CANCER BY MMP-9 MRNA LEVEL IN BLOOD PLASMA | 2020 |
|
RU2745424C1 |
| METHOD FOR DIAGNOSING BREAST CANCER BY LEVEL OF EXPRESSION OF IL-10 AND/OR IL-17 MRNA IN BLOOD PLASMA | 2020 |
|
RU2752971C1 |
| METHOD FOR EVEROLIMUS THERAPY EFFICIENCY PREDICTION FOR PATIENTS WITH METASTATIC RENAL CANCER | 2016 |
|
RU2616533C1 |
| METHOD FOR APPLYING COMBINED IMMUNOTHERAPY OF MALIGNANT BRAIN TUMORS | 2000 |
|
RU2197985C2 |
| METHOD FOR PREDICTING THE COURSE OF CLEAR CELL RENAL CELL CARCINOMA | 2022 |
|
RU2792250C1 |
